Literature DB >> 31578306

Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile.

Julia L Drewes1, Alina Corona1, Uriel Sanchez1, Yunfan Fan2, Suchitra K Hourigan3, Melissa Weidner3, Sarah D Sidhu3, Patricia J Simner4, Hao Wang5, Winston Timp1,2, Maria Oliva-Hemker3, Cynthia L Sears1,6.   

Abstract

BACKGROUNDFecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridioides difficile infection (rCDI) in adults and children, but donor stool samples are currently screened for only a limited number of potential pathogens. We sought to determine whether putative procarcinogenic bacteria (enterotoxigenic Bacteroides fragilis, Fusobacterium nucleatum, and Escherichia coli harboring the colibactin toxin) could be durably transmitted from donors to patients during FMT.METHODSStool samples were collected from 11 pediatric rCDI patients and their respective FMT donors prior to FMT as well as from the patients at 2-10 weeks, 10-20 weeks, and 6 months after FMT. Bacterial virulence factors in stool DNA extracts and stool cultures were measured by quantitative PCR: Bacteroides fragilis toxin (bft), Fusobacterium adhesin A (fadA), and Escherichia coli colibactin (clbB).RESULTSFour of 11 patients demonstrated sustained acquisition of a procarcinogenic bacteria. Whole genome sequencing was performed on colony isolates from one of these donor/recipient pairs and demonstrated that clbB+ E. coli strains present in the recipient after FMT were identical to a strain present in the donor, confirming strain transmission. Conversely, 2 patients exhibited clearance of procarcinogenic bacteria following FMT from a negative donor.CONCLUSIONBoth durable transmission and clearance of procarcinogenic bacteria occurred following FMT, suggesting that additional studies on appropriate screening measures for FMT donors and the long-term consequences and/or benefits of FMT are warranted.FUNDINGCrohn's & Colitis Foundation, the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, the National Cancer Institute, and the Canadian Institutes of Health Research.

Entities:  

Keywords:  Bacterial infections; Colorectal cancer; Gastroenterology; Inflammatory bowel disease; Microbiology

Year:  2019        PMID: 31578306      PMCID: PMC6795395          DOI: 10.1172/jci.insight.130848

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  61 in total

1.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.

Authors:  Mara Roxana Rubinstein; Xiaowei Wang; Wendy Liu; Yujun Hao; Guifang Cai; Yiping W Han
Journal:  Cell Host Microbe       Date:  2013-08-14       Impact factor: 21.023

2.  Screening for enterotoxigenic Bacteroides fragilis in stool samples.

Authors:  Jacqueline I Keenan; Alan Aitchison; Rachel V Purcell; Rosie Greenlees; John F Pearson; Frank A Frizelle
Journal:  Anaerobe       Date:  2016-05-07       Impact factor: 3.331

3.  Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease.

Authors:  George H Russell; Jess L Kaplan; Ilan Youngster; Mariah Baril-Dore; Lili Schindelar; Elizabeth Hohmann; Harland S Winter
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-05       Impact factor: 2.839

4.  A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial.

Authors:  B D Huttner; V de Lastours; M Wassenberg; N Maharshak; A Mauris; T Galperine; V Zanichelli; N Kapel; A Bellanger; F Olearo; X Duval; L Armand-Lefevre; Y Carmeli; M Bonten; B Fantin; S Harbarth
Journal:  Clin Microbiol Infect       Date:  2019-01-04       Impact factor: 8.067

5.  Colorectal Cancer Incidence Patterns in the United States, 1974-2013.

Authors:  Rebecca L Siegel; Stacey A Fedewa; William F Anderson; Kimberly D Miller; Jiemin Ma; Philip S Rosenberg; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

6.  Characterization of the Bacteroides fragilis pathogenicity island in human blood culture isolates.

Authors:  M C Claros; Z C Claros; D W Hecht; D M Citron; E J C Goldstein; J Silva; Y Tang-Feldman; A C Rodloff
Journal:  Anaerobe       Date:  2005-08-15       Impact factor: 3.331

7.  Detection of Bacteroides fragilis enterotoxin gene by PCR.

Authors:  R Shetab; S H Cohen; T Prindiville; Y J Tang; M Cantrell; D Rahmani; J Silva
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 8.  Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection.

Authors:  Y-T Li; H-F Cai; Z-H Wang; J Xu; J-Y Fang
Journal:  Aliment Pharmacol Ther       Date:  2015-12-14       Impact factor: 8.171

9.  The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients.

Authors:  Annemarie Boleij; Elizabeth M Hechenbleikner; Andrew C Goodwin; Ruchi Badani; Ellen M Stein; Mark G Lazarev; Brandon Ellis; Karen C Carroll; Emilia Albesiano; Elizabeth C Wick; Elizabeth A Platz; Drew M Pardoll; Cynthia L Sears
Journal:  Clin Infect Dis       Date:  2014-10-09       Impact factor: 9.079

10.  Protection of the Human Gut Microbiome From Antibiotics.

Authors:  Jean de Gunzburg; Amine Ghozlane; Annie Ducher; Emmanuelle Le Chatelier; Xavier Duval; Etienne Ruppé; Laurence Armand-Lefevre; Frédérique Sablier-Gallis; Charles Burdet; Loubna Alavoine; Elisabeth Chachaty; Violaine Augustin; Marina Varastet; Florence Levenez; Sean Kennedy; Nicolas Pons; France Mentré; Antoine Andremont
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

View more
  10 in total

Review 1.  Effect of gut microbiota in the colorectal cancer and potential target therapy.

Authors:  Junchuan Li; Yuzhou Zhu; Lie Yang; Ziqiang Wang
Journal:  Discov Oncol       Date:  2022-06-24

Review 2.  Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.

Authors:  Rachel Bernard; Suchitra K Hourigan; Maribeth R Nicholson
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

Review 3.  Exploiting unique features of the gut-brain interface to combat gastrointestinal cancer.

Authors:  Alyssa Schledwitz; Guofeng Xie; Jean-Pierre Raufman
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 4.  Role of gut microbiota in epigenetic regulation of colorectal Cancer.

Authors:  Yinghui Zhao; Chuanxin Wang; Ajay Goel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-13       Impact factor: 10.680

Review 5.  Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls.

Authors:  Avnish Sandhu; Teena Chopra
Journal:  Therap Adv Gastroenterol       Date:  2021-12-23       Impact factor: 4.409

6.  Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis.

Authors:  Jasmohan S Bajaj; Amirhossein Shamsaddini; Chathur Acharya; Andrew Fagan; Masoumeh Sikaroodi; Edith Gavis; Sara McGeorge; Alexander Khoruts; Michael Fuchs; Richard K Sterling; Hannah Lee; Patrick M Gillevet
Journal:  Gut Microbes       Date:  2021 Jan-Dec

Review 7.  Next-generation sequencing: insights to advance clinical investigations of the microbiome.

Authors:  Caroline R Wensel; Jennifer L Pluznick; Steven L Salzberg; Cynthia L Sears
Journal:  J Clin Invest       Date:  2022-04-01       Impact factor: 14.808

8.  Age-Matching in Pediatric Fecal Matter Transplants.

Authors:  Abigale D MacLellan; B Brett Finlay; Silke Appel-Cresswell
Journal:  Front Pediatr       Date:  2021-07-16       Impact factor: 3.418

9.  Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes.

Authors:  Varun Aggarwala; Ilaria Mogno; Zhihua Li; Chao Yang; Graham J Britton; Alice Chen-Liaw; Josephine Mitcham; Gerold Bongers; Dirk Gevers; Jose C Clemente; Jean-Frederic Colombel; Ari Grinspan; Jeremiah Faith
Journal:  Nat Microbiol       Date:  2021-09-27       Impact factor: 17.745

Review 10.  Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines.

Authors:  Ross J Porter; Mark J Arends; Antonia M D Churchhouse; Shahida Din
Journal:  J Crohns Colitis       Date:  2021-12-18       Impact factor: 9.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.